Nestlé Purina Research, One Checkerboard Square, Saint Louis, MO 63164, USA.
J Immunol Res. 2021 Jun 19;2021:5545173. doi: 10.1155/2021/5545173. eCollection 2021.
Fel d1 is an important allergen produced by cats that causes IgE reactions in up to 95% of cat-allergic adults. Immunotherapy to reduce human allergy to cats has demonstrated that people have the capacity to produce allergen-specific neutralizing antibodies that block IgE-mediated allergic responses. We wished to determine if "blocking" antibodies could be used to reduce the IgE binding ability of cat allergens prior to their exposure to humans. Here, we describe the characterization of Fel d1-specific antibodies. We demonstrated the efficacy of a rabbit polyclonal and an allergen-specific chicken IgY to bind to Fel d1 in cat saliva and block Fel d1-IgE binding and IgE-mediated basophil degranulation. Fel d1 blocking antibodies offer a new and exciting approach to the neutralization of cat allergens.
Fel d1 是一种重要的过敏原，可导致高达 95%的猫过敏成年人产生 IgE 反应。免疫疗法可降低人类对猫的过敏反应，表明人类具有产生过敏原特异性中和抗体的能力，从而阻断 IgE 介导的过敏反应。我们希望确定在人类接触过敏原之前，“阻断”抗体是否可用于降低猫过敏原的 IgE 结合能力。在这里，我们描述了 Fel d1 特异性抗体的特征。我们证明了兔多克隆抗体和过敏原特异性鸡 IgY 的有效性，可与猫唾液中的 Fel d1 结合，并阻断 Fel d1-IgE 结合和 IgE 介导的嗜碱性粒细胞脱颗粒。Fel d1 阻断抗体为中和猫过敏原提供了一种新颖而令人兴奋的方法。
